Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Whitehawk Therapeutics (WHWK) EBITDA Margin (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed EBITDA Margin for 7 consecutive years, with 1021.71% as the latest value for Q1 2025.

  • On a quarterly basis, EBITDA Margin rose 136402.0% to 1021.71% in Q1 2025 year-over-year; TTM through Sep 2025 was 107.88%, a 13796.0% increase, with the full-year FY2024 number at 245.17%, up 2429.0% from a year prior.
  • EBITDA Margin was 1021.71% for Q1 2025 at Whitehawk Therapeutics, up from 252.74% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 1707.05% in Q2 2021 to a low of 3405.83% in Q1 2021.
  • A 5-year average of 288.74% and a median of 262.27% in 2023 define the central range for EBITDA Margin.
  • Biggest YoY gain for EBITDA Margin was 280518bps in 2022; the steepest drop was -223859bps in 2022.
  • Whitehawk Therapeutics' EBITDA Margin stood at 118.84% in 2021, then plummeted by -124bps to 266.48% in 2022, then rose by 4bps to 256.5% in 2023, then grew by 1bps to 252.74% in 2024, then skyrocketed by 504bps to 1021.71% in 2025.
  • Per Business Quant, the three most recent readings for WHWK's EBITDA Margin are 1021.71% (Q1 2025), 252.74% (Q4 2024), and 173.04% (Q3 2024).